Why the study?
HFpEF presents a major challenge due to the failure of HF drugs to improve outcomes, requiring a better understanding of the complex relationships between aging, comorbidities, and HFpEF.
Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Supports individualized HFpEF management accounting for aging and comorbidities; leaves open optimal targets for prospective trials.
Lin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: